CHICAGO, March 26, 2014 /PRNewswire/ --Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the the IShares NASDAQ Biotechnology ETF (AMEX:IBB-Free Report), Gilead (Nasdaq:GILD-Free Report), Alexion Pharmaceuticals (Nasdaq:ALXN-Free Report), Amgen Inc (Nasdaq:AMGN-Free Report) and Myriad Genetics Inc (Nasdaq:MYGN-Free Report) .
Today, Zacks is promoting its 'Buy' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Tuesday's Analyst Blog:
Are Biotech Stocks Oversold?
After Friday's 4.7% drop, the IShares NASDAQ Biotechnology ETF (AMEX:IBB-Free Report), continued its slide into Monday morning's trading activity. Combined, the two day slide has caused the ETF to drop more than 8%, and has shown no signs of a quick reversal.
The recent selling pattern is believed to be caused by two major factors; First, on Friday, House Democrats on the House's Energy and Commerce Committee requested a briefing on Gilead (Nasdaq:GILD-Free Report) Zacks Rank #1 (Strong Buy), regarding the high price of their new Hepatitis C drug ($84,000 for the drug). Which has sparked some fears regarding potential regulatory risks, and or pricing caps for the sector. Second, jittery retail investors. These Retail investors have seen Biotech stocks consistently appreciate over the past 16-18 months, as they have easily crushed the market (comparison chart below shows the performance of the Nasdaq Biotechnology ETF verse the S&P 500), though they now appear to be facing some selling pressure.
Looking Forward
Currently, the NASDAQ index is more than 400 times PE, and almost 94 times estimated earnings.Naysayers have been searching for bubbles, and with the Fed unwinding the QE, bubbles are bound to appear.It appears as though, Biotech is one of the first areas under attack.
In reality, most analysts believe that this correction is to be expected, and that it will reign in the recent Biotech rally.Even with the Bear Investors looking for a bubble, jittery Retail investors, and House Committee investigations, the street is not too concerned about the recent expected correction.
Stocks to Consider During This Time
Gilead Sciences, Zacks Rank #1 (Strong Buy), seems to have been the catalysts for the recent Biotech downturn, but the investigation does not imply that GILD did anything wrong or is not growing.More specifically, Sovaldi (Hepatitis C drug), saw a 7% week over week increase of total prescriptions written (up from 6835 to 7313) for the drug.It is estimated that Sovaldi will bring in $1.4 billion in Q12014.
Over the past sixty days, Gilead Sciences has seen their Q1 2014 earnings estimates rise from $0.63 to $0.73, and the fiscal year earnings estimates go to $3.76 from $3.33. Furthermore, Gilead has had two consecutive positive earnings surprises, with an average surprise of 6.25%. This indicates that not only can GILD meet expectations, but has a history of beating them as well.
Alexion Pharmaceuticals (Nasdaq:ALXN-Free Report), a Zacks Rank #1 (Strong Buy), recently concluded reimbursement discussions with the French government, which allowed the company to recognize $88 million of additional product sales in Q1 2014. Due to this, management increased guidance, both top and bottom lines, by an additional $62 million and $0.30 of additional upside for the company.Guidance was raised from $2.0-$2.02 billion to $2.15-$2.17 billion.
This change in guidance has caused earnings estimates to rise over the past thirty days; Q1 2014 rose from $0.77 to $0.98, and fiscal year 20014 earnings estimates have risen from $3.50 to $3.81.Moreover, Alexion has had a positive earnings surprise for the past four consecutive quarters, with an average positive surprise of 8.07%.Like GILD, Alexion Pharma has a strong history of not just meeting expectations, but beating them.
Bottom Line
The decline of Biotechnology Stocks over the past two trading days is an anticipated correction for the sector, as well as some fresh political risk.While the sector is declining, there are several companies that can, and will resist the downward trend. This could be a great opportunity to get some value out of the Biotech sector.
While GILD, and ALXN are Zacks Rank #1's, there are a two more Biotech companies that might be worth your consideration, if you are inclined to invest in this sector; Amgen Inc (Nasdaq:AMGN-Free Report), and Myriad Genetics Inc (Nasdaq:MYGN-Free Report), both carrying a Zack's Rank #2 (Buy), and may also be well-positioned for long term gains after this recent slide.
Today, Zacks is promoting its 'Buy' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on IBB - FREE
Get the full Report on GILD - FREE
Get the full Report on ALXN - FREE
Get the full Report on AMGN - FREE
Get the full Report on MYGN - FREE
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumedthat any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein andis subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Logo- http://photos.prnewswire.com/prnh/20101027/ZIRLOGO
SOURCE Zacks Investment Research, Inc.
